DDInter1763 DDInter105
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
A plasma alpha 2 glycoprotein that accounts for the major antithrombin activity of normal plasma and also inhibits several other enzymes. It is a member of the serpin superfamily.
Temsirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Temsirolimus {u} (Compound) treats {v} (Disease) kidney cancer
Temsirolimus {u} (Compound) binds {v} (Gene) CYP3A4
Temsirolimus {u} (Compound) upregulates {v} (Gene) MICU1
Temsirolimus {u} (Compound) is included by {v} (Pharmacologic Class) Protein Kinase Inhibitors
Temsirolimus {u} (Compound) downregulates {v} (Gene) TFDP1
Temsirolimus {u} (Compound) causes {v} (Side Effect) Febrile neutropenia
Temsirolimus (Compound) resembles Everolimus (Compound)
Temsirolimus (Compound) treats kidney cancer (Disease)
Temsirolimus (Compound) binds CYP3A4 (Gene)
Temsirolimus (Compound) upregulates MICU1 (Gene)
Temsirolimus (Compound) is included by Protein Kinase Inhibitors (Pharmacologic Class)
Temsirolimus (Compound) downregulates TFDP1 (Gene)
Temsirolimus (Compound) causes Febrile neutropenia (Side Effect)